| Line Item | 2024-03-31 | Y/Y |
|---|---|---|
| Revenue | $9.9M | +12.1% |
| Cost of Revenue | $10.3M | -50.0% |
| R&D Expense | $4.3M | -16.0% |
| SG&A Expense | $17.2M | +35.8% |
| Operating Income | -$31.7M | +13.1% |
| Pre-tax Income | -$34.3M | +44.7% |
| Net Income | -$34.3M | +44.7% |
| EPS (Basic) | -$2.05 | +98.4% |
| EPS (Diluted) | -$2.05 |
| Line Item | 2024-03-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $1.5M | +2876.0% |
| Short-term Investments | $298K | — |
| Accounts Receivable | $194K | -23.9% |
| Current Assets | $5.1M | +2045.8% |
| Total Assets | $9.2M | -72.4% |
| Current Liabilities | $31.3M | +265.9% |
| Long-term Debt | $3.0M | +0.0% |
| Line Item | 2024-03-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$22.2M | +38.8% |
| Investing Cash Flow | $814 | -100.0% |
| Financing Cash Flow | $20.2M | +110.7% |
| +98.4% |
| Total Liabilities |
| $42.9M |
| +107.6% |
| Stockholders' Equity | -$33.7M | -65.0% |